PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 20260 citationsOpen Access

Generation and characterization of human iPSC-derived NPC1 I1061T/I10161T i 3 Neurons as a model for NPC1 disease

View Full Paper
SSShikha SalhotraNCNiamh X. CawleyCWChristian White

Key Points

  • i3 neurons demonstrate key pathological features of NPC1 disease, including cholesterol accumulation and lysosomal changes.
  • The NPC1 I1061T mutation leads to misfolded proteins that disrupt normal neuronal function.
  • Assessment using human iPSC-derived models allows for an in-depth study of neurodegenerative mechanisms relevant to NPC1.
  • This model could facilitate high-throughput drug screens, aiming to identify treatments that improve NPC1 protein stability.

Abstract

Niemann-Pick disease, type C is an autosomal recessive, fatal, neurodegenerative disorder caused by pathological variants in NPC1 or NPC2 . Dysfunction of either NPC1 or NPC2 results in impaired intracellular cholesterol transport and subsequent storage of unesterified cholesterol in endolysosomal compartments. Earlier cell-based studies utilized patient fibroblasts to study this disease; however, neuronal cells allow for investigation of the neurodegenerative aspect of NPC1. Expression of neurogenin in induced pluripotent stem cells leads to the generation of i 3 Neurons (integrated, isogenic, and inducible), allowing for rapid, synchronized growth of homogenous neurons. In this study, we report the development and characterization of a human iPSC-derived NPC1 I1061T/I1061T i 3 Neuronal model system. NPC1 I1061T is a missense variant resulting in a misfolded protein targeted for proteasomal degradation in the ER. NPC1 I1061T/I1061T i 3 Neurons phenocopied the cellular pathological features of NPC1 disease including endolysosomal cholesterol accumulation, lysosomal morphological changes, and response to the proteostasis modulator, mo56HC. The NPC1 phenotype was alleviated by 2-hydroxypropyl-β-cyclodextrin treatment, a drug demonstrating efficacy both in vitro and in vivo . This NPC1 I1061T/I1061T i 3 Neuronal cell line can facilitate future high-throughput drug and genomic screens, particularly those aimed at identifying proteostasis regulators that improve the expression/stability of the mutant NPC1 protein.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Salhotra et al. (2026) studied this question.

synapsesocial.com/papers/69a7612fc6e9836116a2edbbhttps://doi.org/10.64898/2026.02.11.705111
Ask AI
Helpful
Bookmark
Share
View Full Paper